ViiV Healthcare announced the start of a phase III study to evaluate long-acting injectable cabotegravir for the prevention of HIV...
The FDA Antiviral Drugs Advisory Committee voted to recommend the use of Truvada (emtricitabine/tenofovir disoproxil fumarate) from Gilead Sciences ,as...
Gilead Sciences, Inc. announced that the FDA approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir...
Merck Inc., announced a pause in enrollment for the IMPOWER 22 (MK-8591-022) and IMPOWER 24 (MK-8591-024) Phase III clinical studies evaluating investigational, once-monthly, oral islatravir (ISL), a nucleoside reverse transcriptase translocation inhibitor, for pre-exposure prophylaxis (PrEP) in people at high risk of HIV-1 infection.
Giving a daily Truvada (emtricitabine/tenofovir disoproxil fumarate) pill to help prevent HIV infection could significantly reduce the spread of AIDS,...
Gilead Sciences, Inc. announced that the Antimicrobial Drugs Advisory Committee (AMDAC) of the FDA recommended approval of Descovy...
Gilead Sciences, Inc.announced that the company has submitted a supplemental New Drug Application (sNDA) to the FDA for Descovy (emtricitabine...
Gilead Sciences has submitted a supplemental new drug application to the FDA seeking approval of once-daily Truvada (emtricitabine/tenofovir disoproxil fumarate)...
ViiV Healthcare announced that the FDA approved Apretude (cabotegravir extended-release injectable suspension) the first and only long-acting injectable pre-exposure prophylaxis (PrEP) option to reduce the risk of sexually acquired HIV-1.
ViiV Healthcare announced that the European Medicines Agency (EMA) has validated the company’s marketing authorisation application (MAA) seeking approval of cabotegravir long-acting injectable for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1. Cabotegravir long-acting for HIV prevention is administered six times per year, after initiation.